The HLA system. Second of two parts.

[1]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[2]  Andrew J. McMichael,et al.  Common West African HLA antigens are associated with protection from severe malaria , 1991, Nature.

[3]  P. Bjorkman,et al.  Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor , 1998, Cell.

[4]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[5]  T. Bellón,et al.  Natural killer cell activation and inhibition by receptors for MHC class I. , 1999, Current opinion in immunology.

[6]  M. Sayegh,et al.  Role of indirect allorecognition in allograft rejection. , 1996, International reviews of immunology.

[7]  L. Jorde,et al.  Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. , 1997, American journal of human genetics.

[8]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[9]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[10]  K. Garcia,et al.  Structural basis of T cell recognition. , 1999, Annual review of immunology.

[11]  D. Roopenian,et al.  Minor histocompatibility antigens. , 1997, Current opinion in immunology.

[12]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[13]  A. Hill,et al.  The immunogenetics of human infectious diseases. , 1998, Annual review of immunology.

[14]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[15]  S. Riddell,et al.  Prospects for adoptive T cell therapy. , 1997, Current opinion in immunology.

[16]  J. M. Boss,et al.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. , 1999, American journal of human genetics.

[17]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[18]  P. Parham,et al.  Guilt by association: HLA-B27 and ankylosing spondylitis. , 1990, Immunology today.

[19]  R. Karr,et al.  Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Thorsby,et al.  Invited anniversary review: HLA associated diseases. , 1997, Human immunology.

[21]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[22]  L. Kühn.  Iron overload: molecular clues to its cause. , 1999, Trends in biochemical sciences.

[23]  T. Feltkamp,et al.  The pathogenetic role of HLA-B27. , 1996, Immunology today.

[24]  A. Plebani,et al.  HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. , 1999, The Journal of clinical investigation.

[25]  A. McMichael,et al.  The arrival of HLA class II tetramers. , 1999, The Journal of clinical investigation.

[26]  D. Kwiatkowski,et al.  Association of malaria parasite population structure, HLA, and immunological antagonism. , 1998, Science.

[27]  Andrew W. Liu,et al.  MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. , 1999, The Journal of clinical investigation.

[28]  A. Ahmed,et al.  Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Goedert,et al.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.

[30]  G. Ogg,et al.  HLA-peptide tetrameric complexes. , 1998, Current opinion in immunology.

[31]  H. Auchincloss,et al.  Direct and indirect recognition: the role of MHC antigens in graft rejection. , 1999, Immunology today.

[32]  R. Colvin.  Cellular and molecular mechanisms of allograft rejection. , 1990, Annual review of medicine.

[33]  D. Newton-Nash.  The molecular basis of allorecognition. Assessment of the involvement of peptide. , 1994, Human immunology.

[34]  J. Frelinger,et al.  Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes , 1998, Immunological reviews.

[35]  K. Tadokoro,et al.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[36]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[37]  M. Amagai.  Autoimmunity against desmosomal cadherins in pemphigus. , 1999, Journal of dermatological science.

[38]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[39]  M. Raghavan.  Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[40]  L. Wen,et al.  In Vivo Evidence for the Contribution of Human Histocompatibility Leukocyte Antigen (Hla)-Dq Molecules to the Development of Diabetes , 2000, The Journal of experimental medicine.

[41]  D. M. Penny,et al.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[43]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.